Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.

Alex K. Bryant; Huiying Yin; Matthew J. Schipper; P.A. Paximadis; Thomas Boike; D.P. Bergsma; Benjamin Movsas; Munther Ajlouni; Robert T. Dess; M. Mietzel

doi:10.1200/jco.2021.39.15_suppl.8523

Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.

Identifier:nobleid.org/w1/20260515/56ACFFB5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/56ACFFB5.svg?ark=w1%2F20260515%2F56ACFFB5)](https://nobleid.org/work/w1/20260515/56ACFFB5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.

Identifier:nobleid.org/w1/20260515/56ACFFB5

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/56ACFFB5.svg?ark=w1%2F20260515%2F56ACFFB5)](https://nobleid.org/work/w1/20260515/56ACFFB5)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work